Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933385 | 0.84 | EGLN1 (0.58) | EGLN1FLT1EGLN3FTOKDM5B | |
| SCHEMBL19933384 | 0.84 | EGLN1 (0.57) | EGLN1FLT1EGLN3FTOKDM5B | |
| SCHEMBL19933370 | 0.82 | EGLN1 (0.67) | EGLN1FLT1EGLN3BBOX1 | |
| SCHEMBL19933442 | 0.82 | ATR (0.40) | EGLN1EGLN2ALDH1A1TP53TSHR | |
| SCHEMBL19933496 | 0.82 | EGLN1 (0.67) | EGLN1FLT1EGLN3FTOKDM5B | |
| SCHEMBL19933526 | 0.76 | EGLN1 (0.41) | EGLN1FLT1EGLN3EGLN2FTO | |
| SCHEMBL19933380 | 0.75 | EGLN1 (0.49) | EGLN1EGLN2FTOKDM5BKDM2A | |
| SCHEMBL1923183 | 0.75 | EGLN1 (1.00) | EGLN1FLT1EGLN3FTOBBOX1 | |
| SCHEMBL19933522 | 0.72 | EGLN1 (0.74) | EGLN1FLT1EGLN3FTOBBOX1 | |
| SCHEMBL2774242 | 0.70 | EGLN1 (0.62) | EGLN1FLT1EGLN3BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | AKEBIA THERAPEUTICS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065933-A1 | DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885FLT1 653/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.